Marjolein de Bruin-Weller

List of Publications by Year
in descending order

95 papers	6,205 citations	109137 35 h-index	74018 75 g-index
98 all docs	98 docs citations	98 times ranked	3871 citing authors

#	Article	IF	Citations
1	Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. Journal of Dermatological Treatment, 2022, 33, 1608-1616.	1.1	14
2	Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab â€“ a cross-sectional study from the BioDay registry. Journal of Dermatological Treatment, 2022, 33, 1986-1989.	1.1	4
3	Unraveling heterogeneity in pediatric atopic dermatitis: Identification of serum biomarker based patient clusters. Journal of Allergy and Clinical Immunology, 2022, 149, 125-134.	1.5	21
4	Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. Journal of Allergy and Clinical Immunology, 2022, 149, 977-987.e14.	1.5	66
5	Conjunctivitis in adult patients with moderateâ€toâ€severe atopic dermatitis: results from five tralokinumab clinical trials. British Journal of Dermatology, 2022, 186, 453-465.	1.4	43
6	Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis. American Journal of Clinical Dermatology, 2022, 23, 1-11.	3.3	15
7	Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52ÂWeeks. Dermatology and Therapy, 2022, 12, 223-231.	1.4	7
8	Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12Âyears old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry. Journal of the American Academy of Dermatology, 2022, 87, 1104-1108.	0.6	6
9	Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1ÂYear. Dermatology and Therapy, 2022, 12, 9-13.	1.4	0
10	Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study. Dermatology and Therapy, 2022, 12, 771-785.	1.4	11
11	Ocular surface disease is common in moderateâ€toâ€severe atopic dermatitis patients. Clinical and Experimental Allergy, 2022, 52, 801-805.	1.4	12
12	Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD). Journal of Dermatological Treatment, 2022, 33, 2565-2570.	1.1	3
13	The longâ€term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitisâ€”52 week results from the Dutch <scp>BioDay</scp> Registry. Contact Dermatitis, 2022, 87, 185-191.	0.8	21
14	Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. American Journal of Clinical Dermatology, 2022, 23, 393-408.	3.3	36
15	Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. Dermatology and Therapy, 2022, 12, 1481-1491.	1.4	7
16	Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers. Journal of Allergy and Clinical Immunology, 2021, 147, 189-198.	1.5	61
17	Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1389-1392.e2.	2.0	33
18	Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry. Journal of the American Academy of Dermatology, 2021, 84, 1000-1009.	0.6	51

#	Article	IF	Citations
19	Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 476-485.	1.3	101
20	Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies. Acta Dermato-Venereologica, 2021, 101, adv00402.	0.6	45
21	Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. Journal of Dermatological Treatment, 2021, 32, 164-173.	1.1	15
22	Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four PhaseÂ3 Trials. Dermatology and Therapy, 2021, 11, 1357-1372.	1.4	19
23	Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2021, 397, 2169-2181.	6.3	199
24	Early and Long-Term Effects of Dupilumab Treatment on Circulating T-Cell Functions inÂPatients with Moderate-to-Severe Atopic Dermatitis. Journal of Investigative Dermatology, 2021, 141, 1943-1953.e13.	0.3	43
25	Conjunctival inflammation in dupilumabâ€treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3814-3817.	2.7	12
26	Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis. JAMA Dermatology, 2021, 157, 1047.	2.0	236
27	Nomenclature and clinical phenotypes of atopic dermatitis. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232110029.	1.1	43
28	Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. American Journal of Clinical Dermatology, 2021, 22, 101-115.	3.3	32
29	Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials. Dermatitis, 2021, 32, S81-S91.	0.8	7
30	Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis. Acta Dermato-Venereologica, 2021, 101, adv00585.	0.6	9
31	Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. Dermatology and Therapy, 2021, 11, 2147-2157.	1.4	4
32	Efficacy of Dupilumab in Atopic Dermatitis: The Patientâ€™s Perspective. Dermatology and Therapy, 2021, 11, 2123-2131.	1.4	0
33	Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. Journal of Dermatological Treatment, 2020, 31, 606-614.	1.1	72
34	Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. Journal of the American Academy of Dermatology, 2020, 82, 377-388.	0.6	155
35	The patientâ€reported disease burden in adults with atopic dermatitis: a crossâ€sectional study in Europe and Canada. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1026-1036.	1.3	52
36	Dupilumab is very effective in a large cohort of difficultâ€toâ€treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 116-126.	2.7	105

#	Article	IF	Citations
37	Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial. Dermatology and Therapy, 2020, 10, 1415-1421.	1.4	6
38	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2717-2744.	1.3	220
39	EASI pâ€EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 3287-3289.	2.7	16
40	Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology. BMJ Open, 2020, 10, e033507.	0.8	6
41	Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. American Journal of Clinical Dermatology, 2020, 21, 567-577.	3.3	78
42	Systemic treatment in atopic dermatitis after 2018: from experiencedâ€based treatment to evidenceâ€based treatment?. British Journal of Dermatology, 2020, 183, 987-988.	1.4	0
43	Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials. Journal of the American Academy of Dermatology, 2020, 83, 1499-1501.	0.6	3
44	Twoâ€year drug survival of dupilumab in a large cohort of difficultâ€toâ€treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2376-2379.	2.7	27
45	Management of Ocular Manifestations of Atopic Dermatitis: A Consensus Meeting Using a Modified Delphi Process. Acta Dermato-Venereologica, 2020, 100, adv00264.	0.6	7
46	Management der Dupilumabâ€assoziierten Konjunktivitis beim atopischen Ekzem. JDDG - Journal of the German Society of Dermatology, 2019, 17, 488-492.	0.4	6
47	Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment. Acta Dermato-Venereologica, 2019, 99, 762-768.	0.6	45
48	Time to get rid of the Investigator's Global Assessment as the primary outcome for clinical trials in atopic dermatitis?. British Journal of Dermatology, 2019, 181, 12-13.	1.4	4
49	Responder Threshold for Patient-Oriented Eczema Measure (POEM) and Childrenâ€™s Dermatology Life Quality Index (CDLQI) in Adolescents with Atopic Dermatitis. Dermatology and Therapy, 2019, 9, 799-805.	1.4	24
50	Dupilumab facial redness: Positive effect of itraconazole. JAAD Case Reports, 2019, 5, 888-891.	0.4	42
51	Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment. Clinical and Experimental Allergy, 2019, 49, 1641-1644.	1.4	5
52	European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1644-1659.	1.3	85
53	Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study. Journal of Dermatology, 2019, 46, 680-685.	0.6	46
54	Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. American Journal of Clinical Dermatology, 2019, 20, 443-456.	3.3	130

#	Article	IF	Citations
55	Biomarkers detected in dried blood spots from atopic dermatitis patients strongly correlate with disease severity. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2240-2243.	2.7	7
56	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 753-754.	2.0	2
57	Management of dupilumabâ€associated conjunctivitis in atopic dermatitis. JDDG - Journal of the German Society of Dermatology, 2019, 17, 488-491.	0.4	27
58	Conjunctivitis in dupilumab clinical trials. British Journal of Dermatology, 2019, 181, 459-473.	1.4	288
59	Towards personalized treatment in atopic dermatitis. Expert Opinion on Biological Therapy, 2019, 19, 469-476.	1.4	12
60	Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 341-349.	1.1	8
61	Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis. British Journal of Dermatology, 2019, 180, 1248-1249.	1.4	97
62	Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index. Acta Dermato-Venereologica, 2019, 99, 851-857.	0.6	17
63	Patterns of topical corticosteroids prescriptions in children with asthma. Pediatric Dermatology, 2018, 35, 378-383.	0.5	1
64	Serum biomarker profiles suggest that atopic dermatitis is a systemic disease. Journal of Allergy and Clinical Immunology, 2018, 141, 1523-1526.	1.5	45
65	Conjunctivitis occurring in atopic dermatitis patients treated with dupilumabâ€“clinical characteristics and treatment. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1778-1780.e1.	2.0	132
66	Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels?: reply from the authors. British Journal of Dermatology, 2018, 178, 1220-1221.	1.4	31
67	Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1284-1293.	2.7	546
68	Lymphopenia in atopic dermatitis patients treated with oral immunosuppressive drugs. Journal of Dermatological Treatment, 2018, 29, 682-687.	1.1	4
69	Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. British Journal of Dermatology, 2018, 178, 768-775.	1.4	127
70	Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t. British Journal of Dermatology, 2018, 178, 1083-1101.	1.4	380
71	EASI pâ€•EASI : Predicting disease severity in atopic dermatitis patients treated with cyclosporin A. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 74, 613-617.	2.7	7
72	Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Therapeutic Advances in Chronic Disease, 2018, 9, 159-170.	1.1	25

#	Article	IF	Citations
73	Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis. Journal of Allergy and Clinical Immunology, 2017, 140, 730-737.	1.5	127
74	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet, The, 2017, 389, 2287-2303.	6.3	884
75	Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. Journal of Neurology, 2017, 264, 1155-1164.	1.8	77
76	EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients. Journal of Allergy and Clinical Immunology, 2017, 140, 1703-1705.	1.5	25
77	Current and Future Biomarkers in Atopic Dermatitis. Immunology and Allergy Clinics of North America, 2017, 37, 51-61.	0.7	32
78	Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis. Journal of Allergy and Clinical Immunology, 2017, 139, 1065.	1.5	7
79	The Patient-Reported Disease Burden In Adults With Atopic Dermatitis: A Cross-Sectional Study In Canada and Europe. Value in Health, 2017, 20, A807.	0.1	5
80	Barriers and Facilitators to eHealth Use in Daily Practice: Perspectives of Patients and Professionals in Dermatology. Journal of Medical Internet Research, 2017, 19, e300.	2.1	91
81	ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 729-747.	1.3	329
82	Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice. Journal of the American Academy of Dermatology, 2016, 75, 1257-1259.	0.6	7
83	First experience with extended release tacrolimus in the treatment of adult patients with severe, difficult to treat atopic dermatitis: Clinical efficacy, safety and dose finding. Journal of Dermatological Science, 2016, 81, 66-68.	1.0	3
84	Biomarkers for atopic dermatitis. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 453-460.	1.1	185
85	Serum Creatinine Levels During and After Long-term Treatment with Cyclosporine A in Patients with Severe Atopic Dermatitis. Acta Dermato-Venereologica, 2015, 95, 963-967.	0.6	14
86	Sick Leave and Factors Influencing Sick Leave in Adult Patients with Atopic Dermatitis: A Cross-Sectional Study. Journal of Clinical Medicine, 2015, 4, 535-547.	1.0	8
87	New Developments in Biomarkers for Atopic Dermatitis. Journal of Clinical Medicine, 2015, 4, 479-487.	1.0	26
88	Usage and Users of Online Self-Management Programs for Adult Patients With Atopic Dermatitis and Food Allergy: An Explorative Study. JMIR Research Protocols, 2015, 4, e57.	0.5	10
89	Specific IgE to fish extracts does not predict allergy to specific species within an adult fish allergic population. Clinical and Translational Allergy, 2014, 4, 27.	1.4	24
90	Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity. Journal of the American Academy of Dermatology, 2014, 71, 1160-1166.	0.6	28

#	Article	IF	Citations
91	Modulation of Lymphocyte Function In Vivo via Inhibition of Calcineurin or Purine Synthesis in Patients with Atopic Dermatitis. Journal of Investigative Dermatology, 2012, 132, 2476-2479.	0.3	4
92	Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. Journal of the American Academy of Dermatology, 2011, 64, 275-281.	0.6	77
93	Enteric-coated mycophenolate sodium versus cyclosporin AÂas long-term treatment in adult patients with severe atopic dermatitis: AÂrandomized controlled trial. Journal of the American Academy of Dermatology, 2011, 64, 1074-1084.	0.6	156
94	Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis. Acta Dermato-Venereologica, 0, 102, adv00666.	0.6	6
95	Risk of respiratory tract infections and serious infections in psoriasis patients treated with biologics: Results from the BioCAPTURE registry. , 0, , .		1